All In Biotech

Drug Trial Radar · NCT00444665

Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy

Last checked: Nov 19, 2026Latest source record: Nov 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

750

Planned (sponsor's estimate)

Start

May 2007

Primary completion

Aug 2007

Study completion Aug 2007

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Mar 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.

Conditions

  • Glaucoma

Interventions

  • Travatan-ZDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular Surface Disease Symptoms

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fridley

    Fridley, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.